270 related articles for article (PubMed ID: 34040604)
21. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
22. Antitumor activity of dual blockade of PD-L1 and MEK in NSCLC patients derived three-dimensional spheroid cultures.
Della Corte CM; Barra G; Ciaramella V; Di Liello R; Vicidomini G; Zappavigna S; Luce A; Abate M; Fiorelli A; Caraglia M; Santini M; Martinelli E; Troiani T; Ciardiello F; Morgillo F
J Exp Clin Cancer Res; 2019 Jun; 38(1):253. PubMed ID: 31196138
[TBL] [Abstract][Full Text] [Related]
23. Bispecific Targeting of PD-1 and PD-L1 Enhances T-cell Activation and Antitumor Immunity.
Kotanides H; Li Y; Malabunga M; Carpenito C; Eastman SW; Shen Y; Wang G; Inigo I; Surguladze D; Pennello AL; Persaud K; Hindi S; Topper M; Chen X; Zhang Y; Bulaon DK; Bailey T; Lao Y; Han B; Torgerson S; Chin D; Sonyi A; Haidar JN; Novosiadly RD; Moxham CM; Plowman GD; Ludwig DL; Kalos M
Cancer Immunol Res; 2020 Oct; 8(10):1300-1310. PubMed ID: 32873605
[TBL] [Abstract][Full Text] [Related]
24. PD-L1 targeting high-affinity NK (t-haNK) cells induce direct antitumor effects and target suppressive MDSC populations.
Fabian KP; Padget MR; Donahue RN; Solocinski K; Robbins Y; Allen CT; Lee JH; Rabizadeh S; Soon-Shiong P; Schlom J; Hodge JW
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32439799
[TBL] [Abstract][Full Text] [Related]
25. Late-Stage Tumor Regression after PD-L1 Blockade Plus a Concurrent OX40 Agonist.
Polesso F; Weinberg AD; Moran AE
Cancer Immunol Res; 2019 Feb; 7(2):269-281. PubMed ID: 30563828
[TBL] [Abstract][Full Text] [Related]
26. Activating and propagating polyclonal gamma delta T cells with broad specificity for malignancies.
Deniger DC; Maiti SN; Mi T; Switzer KC; Ramachandran V; Hurton LV; Ang S; Olivares S; Rabinovich BA; Huls MH; Lee DA; Bast RC; Champlin RE; Cooper LJ
Clin Cancer Res; 2014 Nov; 20(22):5708-19. PubMed ID: 24833662
[TBL] [Abstract][Full Text] [Related]
27. Enhancing adoptive cancer immunotherapy with Vγ2Vδ2 T cells through pulse zoledronate stimulation.
Nada MH; Wang H; Workalemahu G; Tanaka Y; Morita CT
J Immunother Cancer; 2017; 5():9. PubMed ID: 28239463
[TBL] [Abstract][Full Text] [Related]
28. Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes.
Liu J; Yang S; Cao B; Zhou G; Zhang F; Wang Y; Wang R; Zhu L; Meng Y; Hu C; Liang H; Lin X; Zhu K; Chen G; Luo KQ; Di L; Zhao Q
J Hematol Oncol; 2021 Jan; 14(1):21. PubMed ID: 33514401
[TBL] [Abstract][Full Text] [Related]
29. Bispecific antibodies enhance tumor-infiltrating T cell cytotoxicity against autologous HER-2-expressing high-grade ovarian tumors.
Oberg HH; Janitschke L; Sulaj V; Weimer J; Gonnermann D; Hedemann N; Arnold N; Kabelitz D; Peipp M; Bauerschlag D; Wesch D
J Leukoc Biol; 2020 Jun; 107(6):1081-1095. PubMed ID: 31833593
[TBL] [Abstract][Full Text] [Related]
30. Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell-recruiting Antibody Optimized for Cytotoxicity and Cytokine Release.
Zuch de Zafra CL; Fajardo F; Zhong W; Bernett MJ; Muchhal US; Moore GL; Stevens J; Case R; Pearson JT; Liu S; McElroy PL; Canon J; Desjarlais JR; Coxon A; Balazs M; Nolan-Stevaux O
Clin Cancer Res; 2019 Jul; 25(13):3921-3933. PubMed ID: 30918018
[TBL] [Abstract][Full Text] [Related]
31. Adoptive immunotherapy of lung cancer with immobilized anti-TCRgammadelta antibody-expanded human gammadelta T-cells in peripheral blood.
Kang N; Zhou J; Zhang T; Wang L; Lu F; Cui Y; Cui L; He W
Cancer Biol Ther; 2009 Aug; 8(16):1540-9. PubMed ID: 19471115
[TBL] [Abstract][Full Text] [Related]
32. Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells.
Yang Y; Zhang X; Lin F; Xiong M; Fan D; Yuan X; Lu Y; Song Y; Zhang Y; Hao M; Ye Z; Zhang Y; Wang J; Xiong D
J Hematol Oncol; 2019 Apr; 12(1):46. PubMed ID: 31023384
[TBL] [Abstract][Full Text] [Related]
33. Enhanced Tumor Control with Combination mTOR and PD-L1 Inhibition in Syngeneic Oral Cavity Cancers.
Moore EC; Cash HA; Caruso AM; Uppaluri R; Hodge JW; Van Waes C; Allen CT
Cancer Immunol Res; 2016 Jul; 4(7):611-20. PubMed ID: 27076449
[TBL] [Abstract][Full Text] [Related]
34. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
35. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
[TBL] [Abstract][Full Text] [Related]
36.
Chen Y; Xue SA; Behboudi S; Mohammad GH; Pereira SP; Morris EC
Clin Cancer Res; 2017 Oct; 23(20):6178-6189. PubMed ID: 28710313
[No Abstract] [Full Text] [Related]
37. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
38. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
[TBL] [Abstract][Full Text] [Related]
39. Bispecific Antibody Expressed by an Oncolytic Herpes Simplex Virus Type 2 Can Transform Heterologous T Cells Into Uniform Tumor Killer Cells.
Jin J; Wang R; Yang J; Hu H; Wang D; Cai L; Fang Z; Dong S; Hu S; Wang Y; Liu B
Hum Gene Ther; 2022 Jun; 33(11-12):649-663. PubMed ID: 35272497
[TBL] [Abstract][Full Text] [Related]
40. Redirection of CD4+ and CD8+ T lymphocytes via an anti-CD3 × anti-CD19 bi-specific antibody combined with cytosine arabinoside and the efficient lysis of patient-derived B-ALL cells.
Fan D; Li W; Yang Y; Zhang X; Zhang Q; Yan Y; Yang M; Wang J; Xiong D
J Hematol Oncol; 2015 Oct; 8():108. PubMed ID: 26444983
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
